Luvadaxistat
- Generic Name
- Luvadaxistat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11F3N2O2
- CAS Number
- 1425511-32-5
- Unique Ingredient Identifier
- 76IC00YRVR
- Background
Luvadaxistat is under investigation in clinical trial NCT03214588 (Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia).
- Associated Conditions
- -
- Associated Therapies
- -
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat
Neurocrine Biosciences' ERUDITE Phase 2 study of luvadaxistat failed to meet primary endpoint for cognitive impairment in schizophrenia, attributed to variability in cognition measures and potential baseline imbalances. The company will halt further development of luvadaxistat and focus on Phase 3 trials for NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder.
Neurocrine Scraps Schizophrenia Candidate After Phase II Failure
Neurocrine Biosciences halts development of schizophrenia drug luvadaxistat after ERUDITE Phase II trial fails to replicate cognitive improvements seen in INTERACT study, attributing failure to variability in cognitive measures and baseline imbalances. The company will focus on other neuropsychiatric assets.
Neurocrine's Phase II schizophrenia trial fails to meet primary endpoint
Neurocrine Biosciences' Phase II ERUDITE trial of luvadaxistat failed to improve cognitive impairment in schizophrenia patients, contrasting with earlier INTERACT study results. The company plans to halt further development of luvadaxistat and focus on advancing NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder.
Neurocrine's schizophrenia trial fails to meet primary endpoint
Neurocrine Biosciences' Phase II ERUDITE trial of luvadaxistat failed to improve cognitive impairment in schizophrenia patients, contrasting with positive results from the INTERACT study. The company plans to halt further development of luvadaxistat and focus on advancing NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder.
Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Neurocrine Biosciences announced that its ERUDITE Phase 2 study of luvadaxistat failed to meet its primary endpoint for improving cognitive impairment in schizophrenia patients, leading to the halt of further development for the compound.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath